论文部分内容阅读
目的探讨恩度(新型重组人血管内皮抑素)联合化疗治疗中晚期非小细胞肺癌的临床疗效及安全性。方法选取2012年9月至2014年在邓州市人民医院接受住院治疗的80例中晚期非小细胞肺癌患者作为研究对象,分为2组,对照组给予单纯的GP化疗方案治疗,研究组在此基础上联合恩度静滴治疗,评价2组临床疗效及不良反应。结果研究组术后6个月有效率显著高于对照组(P<0.05)。2组6个月和12个月生存率比较差异有统计学意义(P<0.05)。对照组不良反应发生率高于研究组。结论恩度联合GP化疗方案治疗中晚期非小细胞肺癌疗效确切,安全可靠,远期生存率相对较高,值得临床加以研究应用。
Objective To investigate the efficacy and safety of Endo (a novel recombinant human endostatin) combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods 80 patients with advanced non-small cell lung cancer who were hospitalized in Dengzhou People’s Hospital from September 2012 to 2014 were selected as the study subjects and divided into two groups. The control group was treated with simple GP chemotherapy. The study group was On this basis, combined with Endo intravenous infusion therapy, to evaluate the clinical efficacy and adverse reactions of the two groups. Results The effective rate in the study group was significantly higher than that in the control group at 6 months postoperatively (P<0.05). The difference in survival rates between the two groups at 6 months and 12 months was statistically significant (P<0.05). The incidence of adverse reactions in the control group was higher than that of the study group. Conclusion Endotherapy combined with GP chemotherapy is an effective, safe and reliable method for the treatment of advanced non-small cell lung cancer. The long-term survival rate is relatively high, and it is worthy of clinical application.